+38 (095) 926-25-85
Trichocosmetics

Modern pathogenetic aspects and principles of treatment of atopic dermatitis

co-authored with Bolotnaya L.A., Korolko Yu.V.

Болотная Л. А., Королько Ю. В. Современные патогенетические аспекты атопического дерматита. Дерматология, косметология, сексопатология. 2004. № 3-4. С. 187–191.


In recent decades the incidence has been rising everywhere in all age groups, but most dramatically in children under 7 years. If in the 1960s it was 0.5-1 % in European countries, today it is 12-15 % [1,10]. In Ukraine the incidence ranges from 3 to 10 (6.5 on average) per 1000 children [4]. The incidence of AD among adults is 1.5-2 % of the general population, varying between countries depending on the level of urbanisation and the ecological cleanliness of the living environment [9]. 

The study of the true incidence is hindered by various factors, one of which is confusion in terminology. AD is a term included in the International Classification of Diseases of the ninth and tenth revisions, recommended by the WHO and adopted in Ukraine; it denotes a skin lesion in children and adults characterised by a chronic, staged course with certain clinical and morphological symptoms in different age periods [1,3,10]. It should be noted that no other dermatosis besides AD has such a variety of synonymous names in different countries and even in different scientific schools of the same country ("Besnier's diathetic prurigo", "endogenous eczema", "neurodermatitis", "allergodermatosis", etc.). The primary registration of the diagnosis is often made by specialists – paediatricians, dermatologists, allergists – under different names, and the same patient may be registered, as it were, with a newly established diagnosis at different age stages (allergic diathesis, infantile eczema, diffuse neurodermatitis). The lack of clear criteria for diagnosing AD also does not help the study of the true incidence.

The formation of skin pathology in AD is an aetiologically multifactorial and pathogenetically multicomponent process involving various regulatory systems and organs of the body. Hereditary predisposition must be taken into account when there is a child with atopy in the family, as this factor significantly affects the prognosis. Thus, if both parents have AD, the child's risk of developing it is 70 %, and if only one parent is ill, the risk falls to 30 % [3,8,13]. 

For the IgE-dependent response to develop and clinical symptoms to appear, various adverse external and internal factors, called risk factors, must act. Numerous studies have proven the leading role of food and inhaled allergens in the formation of AD [1,9,15]. In early childhood, food allergy is the initial sensitisation; in middle and older childhood, in adolescents and adults, household allergens become the more significant triggers. Various endogenous conditions that promote the first manifestation of the disease provide an unfavourable background for the development of AD. The realising factors can conventionally be divided into three groups [3,8].

Perinatal factors are caused by the poor health of the parents and by errors in the management of pregnancy and delivery. Children are found, with varying frequency, to have intrauterine hypoxia, perinatal infections (streptococcal, staphylococcal, urogenital, viral), and pathology of the birth period with injury to the spine, spinal cord or brain. The consequences of these factors in a child with AD may be a reduced and perverted immune response to environmental allergens, and hypothalamic and vertebral dysfunctions with microcirculatory disorders in the organs and skin. Factors of the early postnatal period and early childhood most often lead to the development of the acute phase of AD in the presence of hereditary predisposition and an unfavourable course of the perinatal period. The main factors can be considered to be disturbed digestion and absorption, dyskinesias of the biliary and intestinal tract,  infection of children with helminths and protozoa, vegetovascular disorders, and the development of endogenous intoxication syndrome due to the production of biologically active substances in increased concentrations. The chronic course of AD is maintained by the following factors: dysfunction of the organs and systems of detoxification and protection (insufficiency of the digestive organs and the skin barrier); neurodystrophic and microcirculatory disorders in the internal organs and skin (atrophic gastroduodenitis, impaired liver function, neurovertebral dysfunctions, hypofunction of the adrenal glands); psychosomatic disorders; colonisation of the skin by pathogenic microorganisms (Staphylococcus aureus, Pityrosporum ovale, etc.).

At present a shift in the significance of risk factors is being noted [9,14]. The share of patients with a positive family history is increasing (from 60 to 85 %). Factors of perinatal pathology have come to the fore. As our experience shows, severe forms of AD develop significantly more often in children with a combination of hereditary predisposition to atopy and risk factors. Early onset of the dermatosis, massive long-term drug therapy, an unfavourable psychological climate in the patient's family, and a lack of belief in recovery considerably worsen the prognosis.

Despite many years of research, a complete and convincing concept of the pathogenesis of AD does not exist to date. It is legitimate to assume that one of the reasons for the failure to create a pathogenesis algorithm is the different methodological approaches to its study taken by different specialists. In recent years, however, there has been some redistribution of emphasis in understanding the mechanisms by which pathological changes form in the skin, with the leading importance attached to immune disorders [1,3,6].

The immunopathogenesis of AD paradoxically combines suppression of cellular immunity with activation of cell-mediated allergic reactivity. According to current concepts, the most important link of the immune dysfunction is T-cell immunity, and its disorders show at all levels: quantitative (a reduced number of T cells) and functional (impaired production of interleukins – IL – and cell-mediated reactions) [2,3,10]. Different lymphocyte subpopulations change their activity substantially in AD; a deficiency of suppressor T lymphocytes and an altered ratio of type 1 and type 2 T helpers have been found. The role of these cells has been shown to be ambiguous at different stages of the process: in the acute phase the cells show increased expression of IL-13 mRNA, whereas IL-12 plays the major role in modulating the chronic process [2,11]. 

The most important feature of the pathogenesis of AD is activation of humoral immunity and of eosinophils [3,6]. In AD there is marked overproduction of class E immunoglobulins. Reagins are able not only to bind directly the antigen that causes the atopic process to develop, but also to take an active part in the presentation of the antigen by dendritic cells to T lymphocytes – type 2 T helpers – which plays a significant role in initiating the immunopathological process in the skin. Immunohistochemical studies of the skin of patients with AD have revealed pathological infiltration of the epidermis by activated T lymphocytes and macrophages. Local expansion of type 2 T helpers in the dermis has been shown, producing IL-4, IL-5 and IL-13, which cause eosinophilic reactions and overproduction of IgE, and this determines the clinical manifestations of the disease [3,8,14]. Enhanced synthesis of IL-2, IL-12 and interferons by type 1 T helpers possibly accounts for the maintenance of the long-lasting inflammatory process. 

Therapy of AD today is predominantly pathogenetic and aims to eliminate pathological disorders in organs and systems and to prevent exacerbations of the disease. The programme for managing patients with AD includes several directions: 1) measures to prevent contact with causative factors; 2) correction of background disorders; 3) topical treatment; 4) preventive measures to reduce the risk of an increase in the level of sensitisation and a widening of its spectrum [1,5,15]. 

One of the main technologies of pathogenetic therapy is the antigen-sparing regimen, which is achieved by separating the patient from allergens as completely as possible and includes a number of measures: organising a therapeutic diet and daily living, avoiding polypharmacy and preventive immunisation for certain periods, with subsequent use of gentle immunisation schemes [5,12]. Elimination of biologically active substances and products of disturbed metabolism is achieved by fasting days, tubage, enterosorption (polifepan, carbactin, enterodez, silard) and infusion therapy (neohaemodez, reopolyglucin). The question of methods for sanation of foci of chronic and persistent infection in children with AD remains debatable [3]. Specific therapy should be prescribed and be dominant when the infectious process generalises or is clearly activated. The drugs of choice for treating microbial complications are first- and second-generation cephalosporins and macrolides; when herpetic infection generalises, zovirax or other antiviral drugs are prescribed immediately.

Diagnosis and treatment at the Institute

Get a consultation

An important stage in the treatment of AD is correction of the pathophysiological and pathochemical effects of allergic reactions with anti-mediator therapy (mast cell membrane stabilisers – zaditen, nalcrom; H1-histamine receptor blockers – diazolin, tavegil, loratadine, desloratadine, etc.) [1,6,10]. In the treatment of AD we give preference to second-generation antihistamines, which have high specificity and affinity for H1 receptors, have no M-anticholinergic action, have no sedative or hypnotic effects, act on the early and late phases of the allergic reaction and do not lead to tachyphylaxis. Glucocorticosteroid drugs should be prescribed with particular caution, strictly by indication (in sharp exacerbations accompanied by marked exudation, or when traditional therapy has no effect), in a short course (no more than 7 days).

Correction of background disorders implies normalisation of all organs and systems of the body involved in the atopic process [3,5,6,13]. The function of the digestive organs is restored by normalising the intestinal microflora (bactisubtil, bificol, intestopan, metronidazole,  linex), the processes of digestion and absorption (diet therapy, pancreatin, festal), eliminating motility disorders (papaverine, cerucal, motilium), and restoring liver function and the colloidal state of bile (legalon, lipamide, intake of dietary fibre, mineral waters).

Specific immunotherapy acts on all links of the allergic process and promotes long-term remission. The agents and methods used for this purpose are varied, but the expediency and effectiveness of a number of them (levamisole, untitrated human immunoglobulin preparations, thymic peptides) are always called into question [2,3,12]. Preference should be given to drugs with a polypotent mechanism of action (sodium nucleinate, polyoxidonium, bronchomunal, ribomunil, leukinferon).

In the complex therapy of AD, it is important to use drugs with predominantly metabolic effects, of vitamin and non-vitamin origin (ascorbic acid, phosphorylated forms of vitamins B1 and B6 – cocarboxylase and pyridoxal phosphate, pantothenic acid, pantogam, vitamin A, phosphaden, glutamic acid). To normalise the functions of the central and autonomic nervous systems, anxiolytics with a sedative effect and vegetotropic drugs (bellaspon, cinnarizine, vazobral) are prescribed [1,5,10].

Patients with AD have a number of features caused by the pathological process that affect pharmacodynamics. To prevent the risk of adverse reactions to medications, it is necessary to analyse the allergological and pharmacological history; to prescribe no more than 3-5 drugs; to avoid drugs known to be allergenic; to use parenteral agents in a limited way; to prescribe new drugs of an urgent nature in the first half of the day, and intravenous injections in the presence of a doctor.

Topical therapy is part of the basic standard of treatment of the disease and an integral part of the therapeutic complex. In local therapy the following principles are observed: mandatory correct daily skin care – short cool baths or showers with indifferent cleansing agents, dermatological shampoos, skin moisturising; for exudation and weeping – dermatological lotions and/or wet dressings; for acute inflammation with infiltration and hyperaemia – pastes and ointments containing anti-inflammatory and keratoplastic agents; for chronic skin inflammation with lichenification and dryness – ointments and creams with drugs that have an anti-inflammatory, microcirculation-improving and anti-mediator action [3,7,12].

Practice in recent years shows a prevailing tendency to use, in the therapy of adults and children with AD, a wide range of topical agents containing various glucocorticosteroid hormones as the active substance [1,5,6,13]. Dermatologists now have at their disposal a considerable number of such agents with a universal anti-allergic action: reducing the release of mediators of allergic inflammation, the migration of cells into the lesion zone, and the proliferation of immunocompetent cells in the lesion. Modern topical agents of moderate and strong action that contain no fluorine have proven themselves effective and sufficiently safe. At the same time, in practical terms there remains a danger of local adverse events and complications with long-term and uncontrolled use, and with application to highly sensitive skin (skin atrophy, telangiectasias, hypertrichosis and the formation of steroid resistance are possible) [1,7,15]. There are also a number of restrictions on their use –  they cannot be used in children under 6 months, and halogenated preparations under 2 years; they are to be applied to no more than 20% of the total affected area, and recommended in short courses. Many of the side effects are explained by the fact that corticosteroids do not have a cell-selective mechanism of action. Steroids inhibit collagen synthesis and suppress Langerhans cells up to their complete disappearance from the epidermis, whereas these cells play an important role in the mechanisms of immune surveillance. Therefore the modern conceptual approach to the tactics of topical therapy implies the use of local non-steroidal inhibitors of inflammation and understandably leads to a logical attempt to replace traditional therapy with new kinds of treatment.

A new strategic class of topical agents is non-steroidal drugs with a macrolide structure that contain calcineurin inhibitors and have immunosuppressive activity [7,11]. One such agent, available in domestic clinical practice for only a short time, is pimecrolimus cream 1 % (Elidel). The special structure of the pimecrolimus molecule gives the substance lipophilic properties, which accounts for its high affinity for the skin and the skin selectivity of its anti-inflammatory action. The drug has practically no effect on local and systemic immunological reactions or on the growth of keratinocytes, fibroblasts and endothelial cells, and has no side effects with long-term use. It has been shown that topical use of Elidel cream markedly reduces skin itching after 2-3 days, and on days 3-7 of therapy lowers the activity of allergic inflammation mainly by blocking T-cell and eosinophilic infiltration [11].

Pathogenetically grounded complex therapy of AD using the products of modern pharmaceutical technologies makes it possible to solve the problem of treating this dermatosis to a certain degree – to improve the course markedly and ensure stable remission of the disease, to prevent its recurrence and accordingly to raise the quality of life of both the patients themselves and the members of their families.

References

  1.  Гомберг М.А., Соловьев А.М., Аковбян В.А. Атопический дерматит // Русский медицинский журнал. – 1998. - Т. 6, № 20. – С. 1328-1334.
  2.  Деркач В.В., Просекова Е.В., Вафина Т.П. Цитокины при атопическом дерматите у детей // Медицинская иммунология. – 2003. – Т.5, № 3-4. – С. 434-435.
  3.  Кунгуров Н.В., Герасимова Н.М., Кохан М.М. Атопический дерматит (типы течения, принципы терапии). – Екатеринбург: Изд-во Урал. ун-та, 2000. – 266 с. 
  4. Мавров І.І., Волкославська В.М., Гутнев О.Л., Денисенко О.І. Забруднення атмосфери та захворюваність алергодерматозами в східному та західному регіонах України // Мат. науково-практичної конференції “Захворюваність та вікові особливості шкіри, їх генетична детермівнованість”. – Київ, 2003. – С. 66-69.
  5.  Пампура А.Н., Чебуркин А.А., Смолкин Ю.С. Современные подходы к терапии атопического дерматита // Лечащий врач. – 2000. - № 4. – С. 28-32.
  6.  Сергеев Ю.В. Атопический дерматит. Современные подходы к диагностике, терапии и профилактике // Медицина для всех. – 2001. - № 2 (19). – С. 2-8.
  7.  Смирнова Г.И. Современные технологии местного лечения атопического дерматита у детей // Иммунопатология, аллергология, инфектология. – 2003. - № 3. – С. 75-82.
  8.  Торопова Н.П. Атопический дерматит у детей: механизмы патогенеза // Аллергология. – 1998. - № 3. – С.8-12
  9.  Феденко Е.С. Эпидемиология атопического дерматита // Materia medica. – 2000. –  № 1 (25). – С. 19-25. 
  10.  Bos J.D., Sillevis J.H. Atopic dermatitis // EADV. – 1996. – Vol.7, № 6. – P. 101-114.
  11.  Kapp A. Long-term management of atopic dermatitis in infant with topical pimecrolimus. A nonsteroid anti-inflammatory drug // J. Allergy Clin. Immunol. – 2002. – Vol. 110, № 2. – P. 277-284.
  12.  Leung D.Y. Atopic dermatitis: immonobiology and treatment with immune modulators // Clin. Exp. Immunol. – 1997. – Vol. 107, suppl. 1. – P. 25-30.
  13.  Su Kemp J.C., Narigos A.S., Nolan G.A. Atopic eczema: its impact on the family and financial cost // Arch. Dis. Childhood. - 1997. - Vol. 76, № 2. – P. 159-162.
  14.  Schulz-Larsen F., Hanifin J.M. Epidemiology and pathogenesis of atopic dermatitis // Immunol. Allergy Clin. North. Am. – 2002. – Vol.22, № 4. – P. 1-24.
  15.  Tofte S.J., Hanifin J.M. Current management and therapy of atopic dermatitis // J. Amer. Acad. Dermatol. – 2001. - Vol.44, № 1. – P. 13-16.